Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 6, 2019 - Issue 3
Submit an article Journal homepage
1,678
Views
4
CrossRef citations to date
0
Altmetric
Author's Views

When fat goes down, prostate cancer is on the ropes

Giorgia ZadraDana-Farber Cancer Institute, Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA;Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USACorrespondence[email protected] [email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0002-8123-1358View further author information
ORCID Icon &
Massimo LodaDana-Farber Cancer Institute, Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA;Broad Institute, Cambridge, MA, USA;Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, NY, NY, USAORCID Iconhttp://orcid.org/0000-0001-9674-8379View further author information
ORCID Icon
Article: 1595308 | Received 28 Jan 2019, Accepted 12 Mar 2019, Published online: 16 Apr 2019

References

  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013. PMID: 21376230
  • Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1(10):707–715. PMID: 12939396
  • Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64(6):2212–2221. PMID: 15026365
  • Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469–5477. doi:10.1158/0008-5472.CAN-08-0594. PMID: 18593950
  • Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(2):631–640. doi:10.1073/pnas.1808834116. PMID: 30578319
  • Heuer TS, Ventura R, Mordec K, Lai J, Fridlib M, Buckley D, Kemble G. FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse Xenograft Tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine. 2017 Feb;16:51–62 . doi:10.1016/j.ebiom.2016.12.012. PMID: 28159572.
  • Spick C, Herrmann K, Czernin J. Evaluation of prostate cancer with 11C-acetate PET/CT. J Nucl Med. 2016;57(Suppl3):30S–37S. doi:10.2967/jnumed.115.169599. PMID: 27694168
  • Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, Cacciatore S, Schultz D, Scaglia N, McDunn J, et al. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014;74(24):7198–7204. doi:10.1158/0008-5472.CAN-14-1490. PMID: 25322691
  • Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018;50(2):206–218. doi:10.1038/s41588-017-0027-2. PMID: 29335545
  • Clinical Trials Using FASN Inhibitor TVB-2640. https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/fasn-inhibitor-tvb-2640.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.